More PRNewswire
View Older Stories View Newer Stories-
Johnson Controls Reports Q4 and FY24 Results; Initiates FY25 Guidance
-
QUANTA SERVICES TO PARTICIPATE IN INSTITUTIONAL INVESTOR CONFERENCES
-
Trimble Announces Third Quarter 2024 Results
-
MasTec Senior Management to Present at the Baird 2024 Global Industrial Conference
-
Novelis Reports Second Quarter Fiscal Year 2025 Results
-
FOOT LOCKER, INC. TO REPORT THIRD QUARTER FINANCIAL RESULTS ON WEDNESDAY, DECEMBER 4
-
Honda Motor Co., Ltd. (HMC:NYSE) announced its consolidated financial results for the fiscal first half year ended September 30, 2024
-
Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations
-
Caris Life Sciences Receives FDA Approval for MI Cancer Seek™ as a Companion Diagnostic (CDx) Test
-
CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2024 RESULTS
-
CGI reports fourth quarter and Fiscal 2024 results
-
CVS Health Announces Leadership Appointments
-
Kennametal Announces Fiscal 2025 First Quarter Results
-
Legal Bay Presettlement Funding Reports Settlement Agreements Reached in Zantac Lawsuits
-
iRobot Announces Executive Transitions
-
iRobot Reports Third-Quarter 2024 Financial Results
-
Clarivate Reports Third Quarter 2024 Results
-
Unwrap Festive Flavors with Holiday Drinks at The Human Bean
-
Roundhill Investments Announces XDTE, QDTE and RDTE Distributions for November 8, 2024
-
MEGAROBO Unveils High-Content Cell Imaging System for Advanced Multidimensional Biological Analysis
-
Dallah Hospital Al Nakheel Achieves Global Healthcare Accreditation, Reinforcing its Commitment to Excellence in Medical Travel
-
Esaote Group expands production in India
-
Standard Chartered and Fosun International Sign a Memorandum of Understanding for Strategic Cooperation
-
GoBolt Secures No. 2 Spot on Deloitte's Technology Fast 50 List
-
Lightspeed Ranked 5th Fastest Growing Enterprise--Industry Leader in Deloitte's 2024 Technology Fast 50™ Program
-
Minghui Pharmaceutical Announces Promising Initial Results from Phase I Clinical Trial of MHB039A, a Novel PD-1 x VEGF Bispecific Antibody, in Patients with Relapsed/Refractory Solid Tumors
-
Dingdong (Cayman) Limited Announces Third Quarter 2024 Financial Results
-
Sand Technologies Partners with Envision Racing to Launch AI Solutions for Accelerated Impact
-
So-Young to Report Third Quarter 2024 Financial Results on November 20, 2024
-
Mind Money Joins Global Investment Leaders at SuperInvestor 2024
-
1000 MIGLIA 2025 ENTRIES NOW OPEN
-
Husqvarna Group: Unique data showing how urban green spaces are developing
-
AI ADOPTION IN FP&A SAVES PROFESSIONALS UP TO 200 HOURS AND £100,000 ANNUALLY
-
Autohome Inc. Announces Unaudited Third Quarter 2024 Financial Results
-
HTX Ventures: Fueling Exchanges' Transformation into Hubs for DeFi-related Services through Education and Diversification, Empowering investors to Manage Risks and Liquidity in a Volatile Market
-
Gentoo Media: Invitation to Q3 2024 results presentation
-
CROWN AESTHETICS PROVIDES CAVENDISH CLINICS WITH AWARD-WINNING SKINPEN® PRECISION TO UPGRADE ITS MICRONEEDLING DEVICE OFFERING
-
Chunghwa Telecom Reports Un-Audited Consolidated Operating Results for the Third Quarter of 2024
-
CNOOC Limited Brings On-stream Long Lake NW Project in Canada
-
The 136th Canton Fair Advances High-Quality Development of International Trade with Overseas Buyers Attendance Hitting Record Numbers
-
Bank Leumi to Report 3Q 2024 Financial Results on November 19, 2024
-
In-depth analysis showing robust Diamyd® treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress
-
From Wall Street to Web3: How Triskel is Transforming Financial Access
-
ATRenew to Report Third Quarter 2024 Financial Results on November 20, 2024
-
Thailand announces 2025 as the "Amazing Thailand Grand Tourism and Sports Year"
-
Groupe Mutuel integrates Ada Health's AI-powered care navigation into their member experience across Switzerland to support personalized, streamlined access to care
-
GTN bolsters European growth with FCA authorisation
-
Volta Energy Solutions Hungary pursues 'The Copper Mark' award
-
ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
-
Invitation to presentation of BioArctic's third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET

